Recent research into retatrutide, a dual agonist for GLP-1 and GIP receptors, are demonstrating significant results in treating obesity and type 2 disease. Initial evidence suggest a distinct mechanism contributing to https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/